On February 22, 2019, Edwards Lifesciences Corporation and Edwards Lifesciences, LLC (“Plaintiffs”) filed a complaint against Abbott Cardiovascular Systems, Inc. (“Defendant”) for infringement of U.S. Patent Nos. 6,719,767 (“the ‘767 Patent”), 7,011,669 (“the ‘669 Patent”), and 8,062,313 (“the ‘313 Patent”). The Patents are owned by Edwards Lifesciences Corporation and are drawn to devices and methods of treatment for atrioventricular regurgitation.
The Plaintiffs are asserting that the Defendant is infringing at least claim 14 of the ‘767 Patent, claim 1 of the ‘669 Patent, and claim 1 of the ‘313 Patent by making, using, offering for sale, selling, supplying and/or importing the MitraClip implant and delivery system. The Plaintiffs also allege that the Defendant is inducing infringement by directing others to infringe the patents.
The case remains pending and is captioned 8:19-cv-00345 (C.D. Cal.).
By: April Breyer Menon